The Safety and Effectiveness of SPC3 in HIV-1 Infected Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To assess the effects of two doses of synthetic peptide construction 3 ( SPC3 ) on HIV-1
plasma levels (as measured by RNA PCR Amplicor) and on lymphocyte subsets in patients with
initial viral load above 10,000 copies/ml. To study the safety of SPC3 and the kinetics of
HIV-1 plasma level changes.